Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Froelich L, Johnson G, Patel K, Arciola B, Schmidt C, Albanyan O, Goedel P, Hoster E, Bullinger L, Mackensen A, Locke FL, Von Bergwelt M, Barba P, Jain MD, Subklewe M (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Blood American Society of Hematology

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Pages Range: 2411-2413

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA

DOI: 10.1182/blood-2022-165452

Authors with CRIS profile

Soraya Kharboutli Medizinische Fakultät Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Blood and Marrow Transplant US United States (USA) (US) Vall d'Hebron Institute of Oncology: VHIO ES Spain (ES) Universitätsklinikum Köln DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) State University System of Florida US United States (USA) (US) H. Lee Moffitt Cancer Center & Research Institute US United States (USA) (US) Autonomous University of Barcelona (UAB) / Universitat Autònoma de Barcelona ES Spain (ES)

How to cite

APA:

Buecklein, V.L., Perez-Perez, A., Rejeski, K., Iacoboni, G., Jurinovic, V., Holtick, U.,... Subklewe, M. (2022). Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection. In BLOOD (pp. 2411-2413). New Orleans, LA: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Buecklein, Veit L., et al. "Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022. 2411-2413.

BibTeX: Download